Researchers have deciphered the crystal structure of the HIV co-receptor bound to an indirect inhibitor of viral entry, Celsentri/Selzentry (maraviroc, ViiV Healthcare Co.). The findings could offer valuable clues for how to design the next generation of such inhibitors.